Tag Archive for: Pharmaceutical

Neuraxpharm announces the first launch of BRIUMVI® (ublituximab) in Europe for the treatment of relapsing multiple sclerosis

Germany is the first European country to launch ublituximab, with further launches throughout Europe to follow Only B-cell depleting therapy approved for relapsing multiple sclerosis (RMS) that is administered in a 1-hour infusion*, twice per year** Launch follows ex-US commercialisation*** agreement with TG Therapeutics announced August 2023 Barcelona and Düsseldorf – 26 February 2024 – Neuraxpharm Group […]

Poolbeg Pharma plc – Board Role Change and Launch of Employee Performance Incentive Plan

15 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, “Poolbeg” or the “Company”), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change of Board role and the Remuneration Committee’s approval of the adoption of an Employee Performance Incentive Plan (“EIP”) for a number of […]

Futura Medical extends collaboration with Cooper Consumer Health

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, today announces that it has extended until January 2029 its exclusive licensing agreement with Cooper Consumer Health (“Cooper”), a leading European independent self-care organisation, for the rights to commercialise Eroxon®, the Company’s topical, gel-based Erectile Dysfunction (“ED”) treatment, throughout the European […]

Futura Medical plc – Appointment of Roy Davis as Non-Executive Director

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, today announces the appointment of Roy Davis as a Non-Executive Director with immediate effect. Read more…

European Commission revokes all centrally granted generic marketing permissions for dimethyl fumarate (“DMF”), including Dimethyl Fumarate Neuraxpharm

Decision is not due to any public health concerns regarding generic DMF products Neuraxpharm to swiftly contest this decision at the General Court of the European Union Barcelona and Düsseldorf – 20 December, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces […]